| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 26 | 2024 | 324 | 6.460 |
Why?
|
| Polymorphism, Single Nucleotide | 30 | 2024 | 537 | 3.600 |
Why?
|
| Cardiovascular Diseases | 9 | 2024 | 353 | 2.930 |
Why?
|
| India | 26 | 2022 | 139 | 2.560 |
Why?
|
| Stroke | 5 | 2023 | 241 | 2.550 |
Why?
|
| Genetic Predisposition to Disease | 24 | 2024 | 655 | 2.450 |
Why?
|
| Brain Ischemia | 3 | 2025 | 82 | 2.180 |
Why?
|
| Genetic Variation | 11 | 2021 | 229 | 2.030 |
Why?
|
| Coronary Artery Disease | 8 | 2021 | 216 | 1.870 |
Why?
|
| Genome-Wide Association Study | 20 | 2022 | 226 | 1.860 |
Why?
|
| Gene Frequency | 18 | 2022 | 182 | 1.700 |
Why?
|
| Polymorphism, Genetic | 17 | 2019 | 163 | 1.620 |
Why?
|
| Vitamin D Deficiency | 3 | 2021 | 31 | 1.430 |
Why?
|
| Middle Aged | 37 | 2025 | 6899 | 1.350 |
Why?
|
| Case-Control Studies | 18 | 2020 | 705 | 1.310 |
Why?
|
| Humans | 72 | 2025 | 27115 | 1.290 |
Why?
|
| Metabolomics | 4 | 2025 | 82 | 1.240 |
Why?
|
| Haplotypes | 10 | 2022 | 279 | 1.220 |
Why?
|
| Male | 44 | 2025 | 13019 | 1.150 |
Why?
|
| Obesity | 7 | 2019 | 654 | 1.130 |
Why?
|
| Metabolome | 2 | 2025 | 66 | 1.120 |
Why?
|
| Female | 47 | 2025 | 14633 | 1.080 |
Why?
|
| Risk Factors | 25 | 2021 | 2030 | 1.040 |
Why?
|
| Dyslipidemias | 2 | 2019 | 31 | 1.030 |
Why?
|
| Zebrafish | 2 | 2024 | 95 | 1.010 |
Why?
|
| Aged | 22 | 2025 | 5221 | 0.940 |
Why?
|
| Antigens, Surface | 2 | 2020 | 39 | 0.910 |
Why?
|
| Genotype | 17 | 2021 | 443 | 0.900 |
Why?
|
| Cholesterol Ester Transfer Proteins | 3 | 2012 | 5 | 0.900 |
Why?
|
| Vitamin D | 3 | 2021 | 48 | 0.880 |
Why?
|
| Diabetic Angiopathies | 3 | 2020 | 48 | 0.880 |
Why?
|
| Biomarkers | 6 | 2025 | 738 | 0.840 |
Why?
|
| Cohort Studies | 14 | 2016 | 862 | 0.840 |
Why?
|
| Amino Acids | 2 | 2022 | 81 | 0.840 |
Why?
|
| Adult | 30 | 2024 | 7490 | 0.790 |
Why?
|
| Lipids | 5 | 2013 | 198 | 0.780 |
Why?
|
| Phenotype | 12 | 2022 | 667 | 0.780 |
Why?
|
| Apolipoprotein C-III | 1 | 2021 | 12 | 0.770 |
Why?
|
| Esterases | 4 | 2007 | 16 | 0.730 |
Why?
|
| Blood Glucose | 4 | 2024 | 306 | 0.720 |
Why?
|
| Milk Proteins | 1 | 2020 | 18 | 0.690 |
Why?
|
| Alleles | 16 | 2021 | 345 | 0.680 |
Why?
|
| Pilot Projects | 4 | 2023 | 397 | 0.670 |
Why?
|
| Hypertriglyceridemia | 1 | 2019 | 8 | 0.660 |
Why?
|
| Glycoproteins | 8 | 2004 | 119 | 0.650 |
Why?
|
| PPAR gamma | 2 | 2009 | 29 | 0.640 |
Why?
|
| Pharmacogenetics | 1 | 2018 | 5 | 0.630 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 105 | 0.630 |
Why?
|
| Religion | 2 | 2015 | 23 | 0.610 |
Why?
|
| TCF Transcription Factors | 2 | 2008 | 4 | 0.610 |
Why?
|
| Genetics, Population | 4 | 2020 | 72 | 0.600 |
Why?
|
| Sex Factors | 4 | 2017 | 452 | 0.600 |
Why?
|
| Coronary Disease | 5 | 2017 | 118 | 0.600 |
Why?
|
| Genetic Loci | 5 | 2018 | 75 | 0.600 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 161 | 0.590 |
Why?
|
| Antibodies, Antiphospholipid | 5 | 2007 | 27 | 0.590 |
Why?
|
| Longitudinal Studies | 4 | 2025 | 404 | 0.590 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 3 | 2013 | 8 | 0.580 |
Why?
|
| Body Mass Index | 9 | 2018 | 389 | 0.580 |
Why?
|
| Genetic Association Studies | 5 | 2021 | 110 | 0.580 |
Why?
|
| Metabolic Syndrome | 2 | 2017 | 77 | 0.560 |
Why?
|
| Health Status Disparities | 1 | 2017 | 61 | 0.530 |
Why?
|
| Hydroxycholecalciferols | 1 | 2015 | 1 | 0.520 |
Why?
|
| Emigration and Immigration | 1 | 2015 | 8 | 0.510 |
Why?
|
| Genetic Markers | 3 | 2012 | 93 | 0.500 |
Why?
|
| Apolipoprotein E3 | 1 | 2015 | 12 | 0.500 |
Why?
|
| Drug Resistance | 1 | 2015 | 42 | 0.490 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 106 | 0.470 |
Why?
|
| Casein Kinase II | 1 | 2014 | 17 | 0.460 |
Why?
|
| Telomere | 1 | 2014 | 32 | 0.450 |
Why?
|
| Lipid Metabolism | 2 | 2012 | 121 | 0.450 |
Why?
|
| Hypertension | 2 | 2019 | 305 | 0.450 |
Why?
|
| Triglycerides | 5 | 2021 | 120 | 0.450 |
Why?
|
| Leukocytes | 1 | 2014 | 68 | 0.440 |
Why?
|
| Mutation, Missense | 4 | 2024 | 68 | 0.440 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2025 | 179 | 0.430 |
Why?
|
| Genetic Carrier Screening | 1 | 2013 | 10 | 0.430 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 13 | 0.430 |
Why?
|
| Proteins | 3 | 2012 | 245 | 0.420 |
Why?
|
| Sarcoglycans | 1 | 2013 | 3 | 0.420 |
Why?
|
| Wnt Proteins | 1 | 2013 | 32 | 0.420 |
Why?
|
| Pancreas | 1 | 2013 | 58 | 0.410 |
Why?
|
| Aryldialkylphosphatase | 4 | 2007 | 8 | 0.400 |
Why?
|
| Hypothalamic Diseases | 1 | 2012 | 2 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2012 | 34 | 0.400 |
Why?
|
| Mutation | 4 | 2021 | 818 | 0.380 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2021 | 8 | 0.380 |
Why?
|
| Europe | 4 | 2022 | 97 | 0.380 |
Why?
|
| Receptor, Melatonin, MT1 | 1 | 2011 | 2 | 0.380 |
Why?
|
| Fatty Liver | 1 | 2012 | 55 | 0.370 |
Why?
|
| Insulin Resistance | 2 | 2011 | 171 | 0.370 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2011 | 3 | 0.370 |
Why?
|
| Genetic Linkage | 1 | 2011 | 92 | 0.370 |
Why?
|
| Carrier Proteins | 1 | 2012 | 246 | 0.350 |
Why?
|
| United States | 7 | 2019 | 2060 | 0.350 |
Why?
|
| Adiponectin | 1 | 2009 | 29 | 0.330 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2009 | 5 | 0.330 |
Why?
|
| Models, Biological | 1 | 2012 | 448 | 0.330 |
Why?
|
| Pedigree | 2 | 2020 | 153 | 0.330 |
Why?
|
| Body Height | 2 | 2022 | 58 | 0.320 |
Why?
|
| Cholesterol, HDL | 6 | 2013 | 58 | 0.320 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 32 | 0.320 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 13 | 0.310 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 928 | 0.300 |
Why?
|
| Sequence Analysis, DNA | 4 | 2021 | 365 | 0.290 |
Why?
|
| Prognosis | 2 | 2020 | 763 | 0.280 |
Why?
|
| Consanguinity | 2 | 2019 | 5 | 0.280 |
Why?
|
| Prospective Studies | 2 | 2020 | 1219 | 0.270 |
Why?
|
| Risk | 2 | 2021 | 133 | 0.270 |
Why?
|
| Cognition | 3 | 2019 | 298 | 0.260 |
Why?
|
| Lupus Erythematosus, Systemic | 4 | 2009 | 988 | 0.250 |
Why?
|
| beta 2-Glycoprotein I | 8 | 2009 | 26 | 0.240 |
Why?
|
| Codon | 5 | 1999 | 22 | 0.240 |
Why?
|
| Chromatography, Liquid | 1 | 2025 | 75 | 0.240 |
Why?
|
| Animals | 5 | 2024 | 10078 | 0.240 |
Why?
|
| Linkage Disequilibrium | 5 | 2022 | 107 | 0.230 |
Why?
|
| Genome, Human | 4 | 2022 | 67 | 0.230 |
Why?
|
| Heterozygote | 2 | 2021 | 64 | 0.230 |
Why?
|
| Mass Spectrometry | 1 | 2025 | 188 | 0.220 |
Why?
|
| Chromosome Mapping | 3 | 2022 | 130 | 0.220 |
Why?
|
| Apolipoproteins | 3 | 1999 | 21 | 0.220 |
Why?
|
| Biological Specimen Banks | 1 | 2023 | 8 | 0.220 |
Why?
|
| United Kingdom | 1 | 2023 | 70 | 0.220 |
Why?
|
| Alanine | 1 | 2023 | 40 | 0.210 |
Why?
|
| Genetic Testing | 3 | 2019 | 64 | 0.210 |
Why?
|
| Young Adult | 4 | 2020 | 2625 | 0.210 |
Why?
|
| Pan troglodytes | 2 | 2004 | 12 | 0.200 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 1940 | 0.200 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 3 | 2012 | 5 | 0.200 |
Why?
|
| Exosomes | 1 | 2024 | 92 | 0.200 |
Why?
|
| Cholesterol, LDL | 4 | 2015 | 64 | 0.200 |
Why?
|
| Apolipoproteins E | 3 | 1997 | 44 | 0.200 |
Why?
|
| Sphingolipids | 1 | 2022 | 20 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 5 | 2013 | 262 | 0.190 |
Why?
|
| Base Sequence | 5 | 2013 | 573 | 0.190 |
Why?
|
| Point Mutation | 2 | 2001 | 60 | 0.190 |
Why?
|
| Quantitative Trait Loci | 2 | 2011 | 53 | 0.190 |
Why?
|
| Prevalence | 2 | 2017 | 478 | 0.180 |
Why?
|
| Brain Infarction | 1 | 2020 | 10 | 0.180 |
Why?
|
| Waist Circumference | 2 | 2011 | 18 | 0.180 |
Why?
|
| Lipoproteins | 4 | 2012 | 95 | 0.170 |
Why?
|
| Whole Exome Sequencing | 1 | 2020 | 9 | 0.170 |
Why?
|
| Inflammation | 2 | 2019 | 608 | 0.170 |
Why?
|
| Inbreeding Depression | 1 | 2019 | 1 | 0.170 |
Why?
|
| Body Size | 1 | 2019 | 30 | 0.170 |
Why?
|
| Homozygote | 2 | 2019 | 36 | 0.170 |
Why?
|
| Acute Disease | 1 | 2020 | 153 | 0.170 |
Why?
|
| Animals, Genetically Modified | 1 | 2019 | 54 | 0.160 |
Why?
|
| Risk-Taking | 1 | 2019 | 58 | 0.160 |
Why?
|
| Fertility | 1 | 2019 | 58 | 0.160 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2018 | 1 | 0.160 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2018 | 1 | 0.160 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2018 | 3 | 0.160 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2018 | 4 | 0.160 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2018 | 4 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2020 | 264 | 0.160 |
Why?
|
| Health Status | 1 | 2019 | 145 | 0.150 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 472 | 0.150 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 134 | 0.150 |
Why?
|
| Phospholipids | 2 | 2004 | 75 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2018 | 44 | 0.150 |
Why?
|
| African Americans | 4 | 2018 | 350 | 0.150 |
Why?
|
| Incidence | 1 | 2019 | 553 | 0.140 |
Why?
|
| Blood Pressure | 2 | 2015 | 351 | 0.140 |
Why?
|
| Membrane Transport Proteins | 2 | 2012 | 66 | 0.140 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 930 | 0.130 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 37 | 0.130 |
Why?
|
| Regression Analysis | 3 | 2015 | 209 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2017 | 46 | 0.130 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 4 | 0.130 |
Why?
|
| Genetics, Medical | 1 | 2015 | 3 | 0.130 |
Why?
|
| History, Medieval | 1 | 2015 | 20 | 0.130 |
Why?
|
| Sulfonylurea Compounds | 1 | 2015 | 4 | 0.130 |
Why?
|
| Logistic Models | 2 | 2012 | 398 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2015 | 49 | 0.120 |
Why?
|
| Metformin | 1 | 2015 | 34 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 36 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 204 | 0.120 |
Why?
|
| Hyperglycemia | 1 | 2015 | 78 | 0.120 |
Why?
|
| Glucose | 2 | 2022 | 198 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 12 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2015 | 149 | 0.110 |
Why?
|
| DNA Primers | 2 | 2013 | 143 | 0.110 |
Why?
|
| Antibodies, Anticardiolipin | 2 | 2004 | 23 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2014 | 567 | 0.100 |
Why?
|
| China | 3 | 2014 | 53 | 0.100 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 10 | 0.100 |
Why?
|
| Anthropometry | 2 | 2006 | 94 | 0.100 |
Why?
|
| Receptor, Melatonin, MT2 | 1 | 2011 | 3 | 0.090 |
Why?
|
| Age Factors | 2 | 2012 | 721 | 0.090 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2012 | 67 | 0.090 |
Why?
|
| Fasting | 1 | 2011 | 80 | 0.090 |
Why?
|
| Lupus Nephritis | 2 | 2009 | 99 | 0.090 |
Why?
|
| Molecular Sequence Data | 4 | 2001 | 1036 | 0.090 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2009 | 13 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2009 | 14 | 0.080 |
Why?
|
| Amino Acid Sequence | 3 | 2001 | 674 | 0.080 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 1 | 1 | 2009 | 2 | 0.080 |
Why?
|
| Body Weight | 1 | 2009 | 248 | 0.080 |
Why?
|
| Homeostasis | 1 | 2009 | 115 | 0.070 |
Why?
|
| DNA | 2 | 2001 | 365 | 0.070 |
Why?
|
| Carotid Artery Diseases | 1 | 2007 | 37 | 0.070 |
Why?
|
| Adolescent | 3 | 2018 | 2988 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 331 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 185 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2009 | 595 | 0.070 |
Why?
|
| Linear Models | 1 | 2007 | 201 | 0.070 |
Why?
|
| Receptors, Immunologic | 2 | 1998 | 64 | 0.070 |
Why?
|
| alpha 1-Antichymotrypsin | 2 | 1997 | 6 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2009 | 90 | 0.070 |
Why?
|
| Insulin | 1 | 2008 | 314 | 0.070 |
Why?
|
| Diet, Vegetarian | 1 | 2006 | 2 | 0.070 |
Why?
|
| Child | 3 | 2018 | 2160 | 0.060 |
Why?
|
| Singapore | 2 | 2011 | 4 | 0.060 |
Why?
|
| Protein Isoforms | 2 | 2004 | 118 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2004 | 33 | 0.060 |
Why?
|
| Introns | 1 | 2004 | 41 | 0.060 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2004 | 37 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2004 | 134 | 0.060 |
Why?
|
| Alzheimer Disease | 2 | 1997 | 211 | 0.060 |
Why?
|
| Comorbidity | 2 | 2017 | 252 | 0.050 |
Why?
|
| Sample Size | 1 | 2022 | 17 | 0.050 |
Why?
|
| Binding Sites | 2 | 2009 | 341 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2001 | 47 | 0.050 |
Why?
|
| Exons | 2 | 1999 | 41 | 0.050 |
Why?
|
| Species Specificity | 1 | 2001 | 187 | 0.050 |
Why?
|
| Apolipoprotein A-I | 2 | 1999 | 38 | 0.040 |
Why?
|
| Biological Evolution | 2 | 2015 | 95 | 0.040 |
Why?
|
| NADPH Dehydrogenase | 1 | 1999 | 4 | 0.040 |
Why?
|
| Protein Binding | 2 | 2004 | 636 | 0.040 |
Why?
|
| Complement Inactivator Proteins | 1 | 1999 | 8 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 1999 | 116 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 1999 | 49 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2018 | 7 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1998 | 12 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 1998 | 28 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2018 | 46 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 1998 | 30 | 0.040 |
Why?
|
| HLA-DRB5 Chains | 1 | 2017 | 2 | 0.040 |
Why?
|
| Multigene Family | 1 | 1998 | 50 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2018 | 123 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 76 | 0.040 |
Why?
|
| Asia | 1 | 2017 | 20 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1997 | 26 | 0.040 |
Why?
|
| Isoelectric Focusing | 1 | 1997 | 14 | 0.040 |
Why?
|
| Immunoblotting | 1 | 1997 | 123 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1998 | 388 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 1996 | 18 | 0.030 |
Why?
|
| Odds Ratio | 1 | 1997 | 230 | 0.030 |
Why?
|
| Internationality | 1 | 2016 | 31 | 0.030 |
Why?
|
| Computational Biology | 1 | 2018 | 150 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 145 | 0.030 |
Why?
|
| Exome | 1 | 2016 | 29 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 1996 | 55 | 0.030 |
Why?
|
| Protein Conformation | 1 | 1997 | 253 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 127 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 1996 | 72 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 22 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2016 | 9 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 1997 | 163 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 11 | 0.030 |
Why?
|
| Lung Volume Measurements | 1 | 2015 | 3 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2015 | 16 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 110 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 200 | 0.030 |
Why?
|
| Biological Transport | 1 | 2013 | 112 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2014 | 68 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 481 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 512 | 0.020 |
Why?
|
| London | 1 | 2011 | 9 | 0.020 |
Why?
|
| Pakistan | 1 | 2011 | 10 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 213 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 50 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 2009 | 25 | 0.020 |
Why?
|
| Nigeria | 2 | 1999 | 18 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 626 | 0.020 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 2 | 1998 | 3 | 0.020 |
Why?
|
| COS Cells | 1 | 2004 | 48 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2004 | 54 | 0.010 |
Why?
|
| Epitopes | 1 | 2004 | 180 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 408 | 0.010 |
Why?
|
| NADPH Oxidases | 1 | 1999 | 69 | 0.010 |
Why?
|
| Cardiolipins | 1 | 1999 | 12 | 0.010 |
Why?
|
| Colorado | 1 | 1999 | 47 | 0.010 |
Why?
|
| Clusterin | 1 | 1999 | 5 | 0.010 |
Why?
|
| Urban Health | 1 | 1999 | 12 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 1999 | 41 | 0.010 |
Why?
|
| Codon, Initiator | 1 | 1999 | 6 | 0.010 |
Why?
|
| Genomic Library | 1 | 1999 | 10 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1999 | 17 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1999 | 15 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1999 | 25 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1999 | 31 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1999 | 72 | 0.010 |
Why?
|
| Menopause | 1 | 1998 | 28 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 1998 | 56 | 0.010 |
Why?
|
| Thrombosis | 1 | 1999 | 147 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 109 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 400 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1999 | 293 | 0.010 |
Why?
|
| Liver | 1 | 1999 | 423 | 0.010 |
Why?
|
| Aging | 1 | 1997 | 952 | 0.010 |
Why?
|